Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaMonoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaFludarabine in the treatment of chronic lymphocytic leukemia: a reviewCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaHematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimensPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaPentostatin in chronic lymphocytic leukemiaA new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathwayThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Emerging drugs for chronic lymphocytic leukaemia.The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLA phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationA phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaToll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.How I treat CLL up front.Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioOutcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.Predicting survival in chronic lymphocytic leukemia.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapCurrent and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
P2860
Q24203027-AFDEAFCD-02D6-4C27-95E1-645635A1D95EQ24241519-076351E1-4632-406E-9EC8-A9BF7EA30E38Q24617708-C419A94D-D9ED-47E1-9EC0-8D8F15985E0DQ24645173-341158FF-E2B7-4443-B744-1AC2EED1A1ADQ24681296-4D6A0FB8-BB19-49D6-A31B-F19B0E94FF06Q26783600-5F6EDD39-25B7-4795-B644-E284E3B93DFBQ27021206-2D019AC6-F9A7-4DF9-B8B3-B46329565281Q28261949-8B1DFDE4-892C-4160-AF2B-A7342BE703F1Q28291531-E0CF1657-6B3F-4548-8839-CAA65B04BB38Q28307285-F77B5637-A424-49EF-AFE3-5054F2B2F4FAQ30243968-DAB80B4A-EC3B-4176-9F89-DAA748D29CFAQ30353154-AE3C95EB-184F-4AA6-AFC9-F0EBF93EF544Q31033615-91B4482C-B495-466D-A37F-613A3EA196B7Q33375915-963B06C5-13A4-4E05-ADCB-2697BD2C1BEFQ33380135-F45ED8FF-3149-4418-BA74-A1DE148F666CQ33388795-2B028B48-D0FD-4CAB-BB14-23C3C3F26559Q33394487-70874C65-44D8-4542-B1A6-05D097E692C0Q33396594-2531C346-7C40-4F93-BB82-BAF601B18E34Q33397239-AD1D3FBE-C186-4A28-B43B-B7600A15FAE1Q33406164-00DD369A-145E-4CE7-9ACF-147B3BD3D8B4Q33417117-D84A47CE-57E7-48AB-8348-4D10D966ADC9Q33417548-2D71E716-157B-4F1F-BFF9-8515D8060C32Q33418091-AFA494A5-CCDF-47D6-BBEF-8A45BC008B65Q33591830-50187E69-5078-4C5E-99A4-04D0C204AF63Q33627721-0A4277C0-12EB-4478-BBAB-BC76EEBC8688Q33730841-6A5CF25D-0E09-4AE4-9B16-AA273E5307F3Q33749652-E444DB99-53DE-4864-BD92-5CD472FEA232Q33794311-9AF299ED-B161-4102-BE5D-1D61C0220291Q33816583-4628AA58-DC4E-4A71-9303-61BA05266EBEQ33905245-C45EE99B-0380-40D9-813D-797FD9A6C1C4Q33931707-3A8DBA49-49D3-42D3-A052-1EEB005EFF70Q34008866-26BBA31D-1FC2-4A58-A3F4-63CD1A83E849Q34137158-C238361C-B54E-4347-A40D-696BE5EA6958Q34155701-7885E1C9-E880-4CEC-999C-62261AF252BFQ34202277-85590D5E-8AC1-4D70-A8BD-B17E9205C99FQ34240410-54EFC185-5420-4DD9-A2E3-FD0665A8BD1AQ34257190-719051CF-5BE7-439F-9C6B-799F3B708C0AQ34310845-3C645361-AECB-407A-AA44-F4B7F09EF02EQ34433926-2CF62451-1D74-47C4-A52A-84180940E299Q34440110-78CCE5EE-7A37-4812-B46F-39B93019467E
P2860
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@en
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@nl
type
label
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@en
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@nl
prefLabel
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@en
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@nl
P2093
P50
P356
P1476
Chemoimmunotherapy with fludar ...... chronic lymphocytic leukemia.
@en
P2093
Charles Koller
Deborah Thomas
Kim-Anh Do
Miloslav Beran
P304
P356
10.1200/JCO.2005.12.516
P407
P50
P577
2005-03-14T00:00:00Z